Actinium Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Actinium Pharmaceuticals, Inc.'s operations generated −$24.6m of cash; it spent $104,000 on capital projects, leaving free cash flow of −$24.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Actinium Pharmaceuticals, Inc.: cash flow statement, annual
Fiscal year	2010Dec 2010	2011Dec 2011	2021Dec 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Cash from operations	0	−1	−21	9	−47	−25
Depreciation and amortisation	—	0	1	1	0	0
Stock-based pay	0	2	2	3	4	9
Capital spending	—	—	0	0	0	0
Free cash flow	—	—	−21	8	−47	−25
Free cash flow after stock pay	—	—	−23	5	−51	−34
Shares issued	—	5	35	23	15	—

US$ millions unless shown otherwise. Fiscal quarters.

Actinium Pharmaceuticals, Inc.: cash flow statement, quarterly
Quarter	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026
Cash from operations	−5	−6	28	−6	−8	−6	−5	−5
Depreciation and amortisation	0	0	0	0	0	0	−0	0
Stock-based pay	0	0	0	1	1	0	0	0
Capital spending	0	0	0	0	0	—	—	0
Free cash flow	−5	−6	28	−6	−8	—	—	−6
Free cash flow after stock pay	−6	−6	27	−7	−9	—	—	−6
Shares issued	—	—	—	—	5	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ATNM vs STTK ATNM vs MNOV ATNM vs LGVN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Actinium Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Actinium Pharmaceuticals, Inc.